 |
|
|
| |
Malachite-II : Phase 3b Trial of Ombitasvir/Paritaprevir/r and Dasabuvir + Ribavirin or Telaprevir + Peginterferon/Ribavirin in Peginterferon/Ribavirin Treatment-Experienced Adults With Hcv Genotype 1
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Gregory J Dore1, Brygida Knysz2, Yan Luo3, Ewa Janczewska4, Adrian Streinu-Cercel5, Florin Alexandru Caruntu6, Adriana Motoc7, Wlodzimierz Mazur8, David Shaw9, Istvan Tornai10, Joseph Sasadeusz11, Richard Skoien12, Danielle Sullivan3, Xuan Liu3, Mudra Kapoor3, Yan Liu3, Andrew Campbell3, Thomas Podsadecki3
1Kirby Institute, UNSW Australia, and St. Vincent's Hospital, Sydney, Australia; 2Wrocaw Medical University, Wrocaw, Poland; 3AbbVie Inc., North Chicago, Illinois, United States; 4ID Clinic, Mysowice, Poland; 5Carol Davila University of Medicine and Pharmacy, National Institute for Infectious Diseases "Prof. Dr. Matei Bals", Bucharest, Romania; 6National Institute for Infectious Diseases "Prof. Dr. Matei Bals", Bucharest, Romania; 7Hospital of Infectious Diseases Dr. Victor Babes, Bucharest, Romania; 8Clinical Department of Infectious Disease, Medical University of Silesia, Katowice, Poland; 9Royal Adelaide Hospital, Adelaide, Australia; 10University of Debrecen, Department of Medicine, Division of Gastroenterology, Debrecen, Hungary; 11Royal Melbourne Hospital, Melbourne, Victoria, Australia; 12Royal Brisbane and Womens Hospital, Brisbane, Queensland, Australia
|
| |
|
|
|
|
|
